Skip to content

Fulgent Genetics, Inc. FLGT Laboratory Services — Goodwill

Other segment segments

Therapeutic Development
$22.35M+1.1%

Similar metrics at other companies

Thermo Fisher Scientific logo
TMOLaboratory Products and Biopharma Services — Goodwill
$24.23B+1.9%
Labcorp Holdings logo
LHBiopharma Laboratory Services — Goodwill
$1.35B
Labcorp Holdings logo
LHBiopharma Laboratory Services — Goodwill acquired, excluding measurement period adjustments
$0
Ciena logo
CIENGlobal Services — Goodwill
$0
Rockwell Automation logo
ROKLifecycle Services — Goodwill
$495M-23.4%
RadNet logo
RDNTImaging Center — Goodwill
$758.65M+19.9%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s laboratory services — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s laboratory services — goodwill?
Fulgent Genetics, Inc. (FLGT) reported laboratory services — goodwill of $31.38M in Q1 2026.
What does laboratory services — goodwill mean?
This metric represents the cumulative carrying value of goodwill allocated to the laboratory services segment, reflecting the excess purchase price paid for past acquisitions. It is a critical figure for assessing the long-term value of previous strategic investments and potential future impairment risks.